Post

New research · Ophthalmology
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 4d
Cohort studyGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Yaru Zou, Mingming Yang, Jing Zhang … Koju Kamoi
Read paper
OphthalmologyCohort study

Adding a steroid injection to adalimumab was linked to faster improvement in uveitic macular edema.

Sub-Tenon's triamcinolone bridging to adalimumab therapy in refractory noninfectious uveitic macular edema.

Yaru Zou … Koju Kamoi
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
Background

Noninfectious uveitic macular edema (uveitic macular edema) is a major cause of visual impairment and remains challenging in refractory cases.

Purpose

This study compared adalimumab monotherapy with adalimumab combined with sub-Tenon's triamcinolone acetonide (STTA) bridging therapy in refractory noninfectious uveitic macular edema.

Methods

In this retrospective longitudinal cohort study, 30 patients (44 eyes) with refractory noninfectious uveitic macular edema treated with adalimumab (2015-2025) were included.

n = 44 eyes
Results

adding the steroid shot sped up eye swelling improvement compared with adalimumab alone

HR by subgroup · 95% CI
null = 1
shorter time to improvement
2.85
did not differ significantly
0.71
More results

Adjusted analyses showed greater visual improvement in the bridging group at 12 months (difference 0.307 LogMAR; p < 0.001) and at 15, 24, and 36 months (p < 0.05).

Greater central subfield thickness reductions were observed at 3, 18, 21, and 36 months (p < 0.05).

More results

Relapse risk did not differ significantly (HR 0.711, 95% CI 0.155-3.272; p = 0.662).

IOP changes were generally comparable.

“
Conclusion

Adalimumab combined with STTA bridging therapy was associated with earlier anatomical improvement and additional visual benefits compared with adalimumab monotherapy, without increased relapse risk.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving